Clinical trial

A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

NCT00314574

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-12-01

PhasePHASE3

Study timeline

Study start (unknown)2005-12-01Date precision: month

Registry last updated2012-02-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

omalizumab (Xolair)DRUG

placeboDRUG

corticosteroidsDRUG

long-acting beta-agonistsDRUG

Sponsors & collaborators

Genentech, Inc.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00314574 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.